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Abstract 29 
Background 30 
Diagnosing and managing Type 2 Diabetes Mellitus (T2DM) among people living with HIV 31 
(PLHIV) is becoming more important as the HIV-infected population ages and becomes 32 
increasingly comorbid. Data on incidence of  T2DM in PLHIV in Sub-Saharan Africa is 33 
scarce. 34 
Methods 35 
We analyzed data for all HIV-infected patients older than 16 years who attended Newlands 36 
Clinic between March 1, 2004 and April 29, 2015. The clinic considers patients whose 37 
random blood sugar is higher than 11.1 mmol/L and which is confirmed by a fasting blood 38 
sugar higher than 7.0 mmol/L to have T2DM. T2DM is also diagnosed in symptomatic 39 
patients who have a RBS  >11.0 mmol/l. Risk factors for developing T2DM were identified 40 
using Cox proportional hazard models adjusted for confounding. Missing baseline BMI data 41 
were multiply imputed. Results are presented as adjusted hazard ratios (aHR) with 95% 42 
confidence intervals (95%CI).  43 
Results 44 
Data for 4,110 participants were included: 67.2% were women; median age was 37 (IQR:31-45 
43) years. Median baseline CD4 count was 197 (IQR: 95-337) cells/mm3. The proportion of 46 
participants with hypertension at baseline was 15.5% (n=638). Over a median follow-up time 47 
of 4.7 (IQR:2.1-7.2) years, 57 patients developed T2DM; the overall incidence rate was 2.8 48 
(95%CI: 2.1 – 3.6) per 1000 person-years of follow up. Exposure to PIs was associated with 49 
T2DM (HR: 1.80, 95%CI: 1.04-3.09). In the multivariable analysis, obesity (BMI>30kg/m2)  50 
(aHR=2.26, 95%CI: 1.17-4.36), age >40yrs (aHR=2.16, 95%CI: 1.22-3.83) and male gender, 51 
(aHR=2.13, 95%CI: 1.22-3.72) were independently associated with the risk of T2DM. HIV 52 
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related factors (baseline CD4 cell count and baseline WHO clinical stage) were not 53 
independent risk factors for developing T2DM. 54 
Conclusion 55 
Even though the incidence of T2DM in this HIV cohort was lower than has been observed in 56 
other cohorts, our results show that risk factors for developing T2DM among HIV infected 57 
people are similar to the general population. HIV-infected patients in sub-Saharan Africa 58 
need a comprehensive approach to care that includes better health services for prevention, 59 
early detection and treatment of chronic diseases especially among the elderly and obese. 60 
Key words: Type 2 Diabetes mellitus, Zimbabwe, HIV infection 61 
  62 
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Background 63 
Acess to antiretroviral therapy (ART) has reduced the Human Immunodeficiency Virus (HIV) 64 
associated morbidity and mortality among people living with HIV (PLHIV). However, access to  65 
long term ART may be associated with toxicities including hyperglycaemia and diabetes 66 
mellitus [1]. As PLHIV live longer, they are likely to develop comorbidities such as Type 2 67 
Diabetes Mellitus (T2DM). Furthermore, the prevelance of noncommunicable diseases is 68 
increasing in low and middle income countries [2], hence PLHIV in these countries are faced 69 
with a dual burden of disease as they grow older. Traditional and well established risk factors 70 
of development of T2DM in non HIV infected patients include older age, hypertension, obesity 71 
and physical inactivity [3]. Factors associated with the occurrence of T2DM in HIV-infected 72 
patients are complex. They include the effects of HIV itself, which is a chronic inflammatory 73 
and insulin-resistant condition, genetics, cigarette smoking, physical inactivity, obesity, aging 74 
and the toxic effects of ART [4] . As persons infected with HIV are surviving longer due to ART 75 
uptake, T2DM and cardiovascular diseases are increasingly noted [5], [6]. The WHO 76 
STEPwise chronic disease risk factor surveillance programme (STEPS) quantifies the burden 77 
of diabetes in sub-Saharan Africa, which varies widely; it is 6.1% in Cameroon, over 7.1% in 78 
Congo, and 10.2% in Zimbabwe [7]. In a recent cross sectional facility based study, 2.1% 79 
(95%CI:1.3-3.2%) of people living with HIV in Zimbabwe had cormobid T2DM [8]. Results from 80 
the phase 3 HPTN 052 randomised controlled trial done in Uganda and Zimbabwe showed a 81 
very low event rate for diabetes mellitus (9 new cases in 1761 patients) among HIV infected 82 
patients on ART [9].  83 
There is documented evidence of an increase in the burden of T2DM in Zimbabwe [10]. In 84 
2015, 209,800 cases of diabetes were recorded in the country and these contributed to the 85 
national adult prevalence of 2.9% [11]. However, the incidence of  T2DM among HIV 86 
infected individuals in Zimbabwe is unknown. The increasing burden of non-communicable 87 
diseases among PLHIV will increase the costs of comprehensive healthcare provision 88 
especially in resource limited settings. Despite this double burden, there is a dearth of 89 
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literature surrounding diabetes and HIV research in Zimbabwe. Given the evidence 90 
concerning HIV’s role (via ART mediated pathways) as a potential risk factor for diabetes, 91 
there is a need for this research to be carried out in Zimbabwe. The objective of this study 92 
was to assess the incidence and associated risk factors of new onset T2DM in a cohort of 93 
HIV infected individuals receiving ART at an outpatient clinic in Zimbabwe.   94 
Methods 95 
Study setting 96 
Newlands Clinic (NC) is a family-centered, nurse-based and doctor supervised HIV 97 
treatment center in Harare, Zimbabwe. Nurses provide routine HIV care to patients and 98 
doctors consult all patients with new clinical complains and / or abnormal laboratory results. 99 
It is a part of the coordinated public-private partnership between the Ministry of Health and 100 
Child Care and several private organisations that provide HIV treatment in Zimbabwe. NC 101 
provides access to care and treatment to approximately 5,500 HIV-1 infected paediatric, 102 
adolescent and adult patients. Patient care follows the Zimbabwe national guidelines [12]. 103 
Patients enrolled at NC have similar demographic and socio-economic characteristics to 104 
those in the national OI / ART program [13]. NC uses the same guidelines for initiation of 105 
ART as the national program. As part of routine HIV care, the following laboratory test are 106 
done at least once every year: Full Blood Count (FBC), serum creatinine clearance, liver 107 
function tests, CD4 cell count, HIV viral load and urinalysis (since 2013). The clinic does not 108 
offer routine testing for lipids and HbA1c. 109 
Study Procedures / Methods 110 
The clinic includes a laboratory and a pharmacy with quick turnaround times for laboratory 111 
investigations and convenient drug pick-up after consultations. These services are provided 112 
free to patients.  All clinic patients are screened for T2DM with random venous blood 113 
glucose measurements performed at baseline and routinely once a year by the laboratory.  114 
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Diagnosis of T2DM was based on two different criteria defined by the American Diabetes 115 
Association [14]. 1) If a patient had an elevated random blood glucose measurement 116 
of  >11.0 mmol/l, a fasting plasma glucose (FPG) test was done to screen for T2DM. Fasting 117 
blood sugar is measured after the patient has not consumed food or drink (except water) for 118 
at least 8 hours. If the FPG value was >7.0 mmol/l, the patient was diagnosed with T2DM. 2) 119 
Patients who presented with clinical signs and symptoms of hyperglycemia, such as thirst, 120 
polyuria, weight loss and blurred vision were screened immediately by measuring random 121 
blood sugar; if sugar was elevated (>11.1 mmol/l), they were diagnosed as T2DM. All 122 
patients had access to blood sugar measurements. Screening and diagnosis of T2DM is 123 
done by a doctor. There has not been any patient diagnosed of type 1 diabetes mellitus at 124 
the clinic to date and hence type 1 diabetes mellitus was not part of this analysis. All patient 125 
data are entered into an electronic medical record system since the clinic was started in 126 
2004. 127 
Ethical Approval 128 
Newlands Clinic is part of the International epidemiologic Databases to Evaluate AIDS-129 
Southern African Region (IeDEA-SA) [15]. Patients provided written informed consent 130 
allowing their clinic data to be used for research analysis to answer epidemiological 131 
questions. This study was approved by the Medical Research Council of Zimbabwe 132 
(Approval number: MRCZ/A/1336).  133 
Inclusion criteria and definitions 134 
All patients aged 16 years and above at ART commencement receiving care at Newlands 135 
Clinic in the period 01 March 2004 to 29 April 2015 were eligible for analysis. Baseline 136 
values / variables were at commencement of ART.  Patients who were diagnosed with T2DM 137 
before or at the time they started ART were excluded from this analysis. Incident T2DM was 138 
defined as a documented new diagnosis of T2DM after ART commencement. Hypertension 139 
was defined as a documented systolic pressure greater than 140 mm Hg and / or diastolic 140 
7 
 
pressure greater than 90 mm Hg measured on at least 2 different days or receiving 141 
antihypertensive medicines. All patients with a diagnosis of hypertension are on anti-142 
hypertensive medicines such as atenolol, enalapril, spironolactone, amilodipine and 143 
antihypertensive medicines are not used for non-hypertensive heart diseases at NC. 144 
Baseline values of CD4 and BMI were the closest values, within 3 months before or after 145 
start of ART. ART was defined as a regimen of at least three antiretroviral drugs from any 146 
drug class. Loss-to-follow-up (LTFU) was defined as failing to attend a scheduled clinic 147 
appointment for at least 90 days without documentation of death or transfer to another clinic.   148 
Statistical analysis 149 
The overall and stratified incidence rates of T2DM were calculated as the number of new-150 
onset T2DM cases, divided by the total number of person-years (PY) of follow-up. We 151 
calculated T2DM incidence rates for the whole observation period and did not consider 152 
interruptions or treatment changes to ART. Data was complete for all variables except 153 
baseline BMI where 8.7% (n=357) were missing. We imputed these missing BMI values 154 
based on the other characteristics at baseline, and whether the patient developed T2DM or 155 
not. Analyses were done for each of the 20 imputed datasets and we used Rubin’s rule to 156 
combine results [16].  We also did a complete case analysis. 157 
We used crude and adjusted Cox proportional hazards models to describe risk factors for 158 
incident T2DM and checked for proportional hazard assumptions using Schoenfold 159 
residuals. Use of protease inhibitors (PI) was assessed in the univariable analysis only and 160 
not in multivariable analysis because it is in the causal pathway for T2DM. We measured 161 
follow-up time from day of ART initiation until the date of T2DM diagnosis, the last follow-up 162 
visit, or death, whichever occurred first. We considered the following explanatory variables at 163 
start of antiretroviral therapy: age (<40 and ≥40 years); gender; baseline CD4 count category 164 
(<200 and ≥200 cell/ mm3); baseline BMI (<30 and ≥30 kg/ m2, missing baseline BMI data 165 
was imputed as a continuous variable); hypertension;  and, WHO clinical stage (stages 1 166 
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and 2 vs stages 3 and 4). Results are presented as incidence rates per 1000 person years, 167 
crude and adjusted hazard ratios (HR) with 95% confidence intervals (CI). All statistical 168 
analyses were performed in Stata version 13.0. (StataCorp, College Station, Texas, USA).  169 
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Results 170 
Patient characteristics 171 
The Clinic database had 5,467 patient records. We excluded 42 patients who had prevalent 172 
T2DM, 6 participants who had not started ART and 1,309 who were children <16 years old. 173 
We analysed data for 4,110 patients, of whom 67.2% (n=2,761) were women. The 174 
characteristics of the participants at start of ART are shown in Table 1. Median age of 175 
participants was 37 years (IQR: 31-43); median baseline CD4 count was 197 cells/mm3 176 
(IQR: 95-337). Overall 46.6% (n=1,917)  participants were in WHO stage 3 or 4. Prevalence 177 
of obesity was 9.6% (n=3753).  Among the 16% (n=638) patients with hypertension, 178 
prevalence of obesity was almost twice as high (30.2%; n=110) when compared to those 179 
without hypertension. Median follow-up time for study participants was 4.7 years (IQR 2.1 - 180 
7.2). At the time of data abstraction (29 April 2015), 78% (n= 3,208) participants were still in 181 
care, 8.9% (n=364) had died, 5.3% (n=217) were LTFU and  7.8% (n=321) were transferred 182 
to other HIV treatment centres.  183 
 184 
Incidence of T2DM  185 
The number of new T2DM diagnoses over the 20,504 PY of follow-up was 57; overall 186 
incidence rate was 2.8 per 1000 PY (95% CI: 2.1-3.6). There were 5 new T2DM diagnoses 187 
among patients who deceased and 4 among patients transferred out. None of the new 188 
T2DM diagnoses were diagnosed in pregnancy. The incidence rate of T2DM was higher in 189 
men than in women.The incidence rate of T2DM increased with age from 0.48 / 1000 PY 190 
(95%CI: 0.07-3.37) among patients younger than 25 years to 8.35 / 1000 PY (95%CI: 5.11-191 
14.32) in those 50 years and above. The incidence rate also increased with an increase in 192 
BMI from a rate of 0 /1000 PY in patients with a BMI of < 18 kg/m2 to a rate of 5.84 / 1000 193 
PY (95%CI: 3.24-10.55) in those who had a BMI of at least 30 kg/ m2. Hypertensive 194 
participants had a higher incidence rate than those without hypertension. We did not see any 195 
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trend in the incidence of T2DM over the years associated with the change in national ART 196 
guidelines. Table 1 higlights the incidence of T2DM for various patient categories. In 197 
univariable analysis, patients who had used protease inhibitors were more likely to develop 198 
T2DM than those who had not (RR=1.80, 95%CI: 1.04-3.09). Table 2 shows the results of 199 
the univariable and multivariable analyses that identified risk factors of diabetes.  200 
In the multivariable analysis, men were more likely to develop T2DM than women 201 
(aHR=2.13). Patients >40 years old had a higher risk of developing T2DM (aHR=2.16) than 202 
patients <40 years old. Obesity (BMI >30 kg/m2) was an independent risk factor for T2DM 203 
(aHR=2.26). HIV-related characteristics (baseline WHO stage and baseline CD4 count) were 204 
not associated with risk of developing diabetes. There was no evidence of proportional 205 
hazard assumptions violation (p=0.19).  206 
 207 
Discussion 208 
Overall incidence of T2DM in this cohort of HIV-infected people was 2.8 per 1000 PY of 209 
follow-up. The incident rate increased with increases in age and BMI. We identified the 210 
following independent risk factors for developing T2DM: Age > 40 years, male gender, and 211 
obesity. HIV-related factors (baseline CD4 cell count and baseline WHO clinical stage) were 212 
not independent risk factors for the development of T2DM. We did not include use of PIs in 213 
the multivariable model because PI use is in the causal pathway for pathogenesis of T2DM 214 
and hence cannot be controlled for, however, use of PIs was a significant risk factor in the 215 
univariable analysis. 216 
We found a much lower T2DM incidence rate than has been reported in other studies. A 217 
study from Thailand showed an incidence rate of 5.0 per 1000 PY among patients living with 218 
HIV [17]. The Data collection on Adverse events of Anti-HIV Drugs (D.A.D) study showed an 219 
incidence rate of  5.7 per 1000 PY [18] and in the Swiss HIV Cohort study the incidence rate 220 
was  4.4 per 1000 PY [4]. In a study done in South Africa, Karamchand et al found a crude 221 
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incidence rate of 13.2 per 1000 PY among HIV infected adults on first-line ART [19]. To the 222 
best of our knowledge, there are no studies that have looked at the incidence of T2DM in 223 
either HIV positive or negative people in Zimbabwe hence we are not able to compare our 224 
findings with national statistics. Several factors might explain the discrepancy between our 225 
study results and other studies. The median BMI of 22.3 kg/m2 among our participants was 226 
much lower than, for example, in the Swiss HIV Cohort. We used routinely collected clinic 227 
data where patients were screened for T2DM during regular clinic visits and under-reporting 228 
is possible. Routine haemoglobin A1C measurements would have better estimated the 229 
incidence of T2DM in our cohort, but the incidence of T2DM we found in patients over 40 230 
years of age  was still comparable to the findings of both Swiss HIV cohort study and the 231 
D.A.D study [4], [18]. 232 
This analysis identified key risk factors for the development of T2DM among patients living 233 
with HIV. These risk factors are similar to those identified among the general population and 234 
are also consistent with findings from other cohort studies [4], [18]. Not surprisingly, the 235 
incidence rate increased with age and was highest in the patients above 50 years of age, 236 
highlighting the increased burden of health problems among individuals who are ageing with 237 
HIV. Our findings of an increased risk of T2DM with increasing age and BMI are consistent 238 
with findings from studies that have looked at risk factors of T2DM among both HIV positive 239 
and HIV negative individuals [20]. As in people not infected with HIV, age is an important risk 240 
factor for both T2DM and cardiovascular diseases. Since aging cannot be avoided, it is 241 
important to regularly screen the elderly for diseases such as diabetes. While studies have 242 
demonstrated a lower BMI in HIV-infected patients with diabetes compared to non-infected 243 
matched cohorts [21], the association between T2DM and obesity persists in HIV infected 244 
patients. For example, Galli et al. found that the prevalence of T2DM in those with normal 245 
BMI was 3.2% in HIV patients and 1.1% in HIV uninfected. However, in the overweight and 246 
obese categories, T2DM prevalence rose to 3.9% and 12.7% among HIV infected patients 247 
compared with 3.1% and 7.8% respectively in HIV-uninfected patients [22]. HIV treatment 248 
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programs should educate patients on the dangers of obesity so as to minimise the risk of 249 
developing T2DM. Furthermore, elderly PLHIV should be educated on the association of 250 
ageing and the risk of developing T2DM.  In the univariable analysis, our results showed that 251 
patients who had used PIs (ritonovir boosted atazanavir and / or lopinavir) were 1.8 times 252 
more likely to develop new-onset T2DM. These findings are consistent with other studies 253 
that have demonstrated the association between PI use and metabolic complications such 254 
as T2DM [20], [23]. Use of ART medicines has increasingly become important as a potential 255 
risk factor for T2DM. In a review article on diabetes and HIV, Murphy and Gerard report that 256 
PLHIV following treatment with some first generation ART drug classes (protease inhibitors) 257 
had higher rates of diabetes incidence compared to HIV negative participants [24]. In South 258 
Africa, it was recently reported that treatment with efavirenz, as well as stavudine and 259 
zidovudine, increased the risk of incident diabetes [25]. In this cohort, we could not assess 260 
the association between efavirenz or nevirapine with T2DM because efavirenz became 261 
available only a year ago and before that all patients received nevirapine as part of their first 262 
line ART regimen. We could also not assess the associations of different PIs because 263 
Patients have received both Lopinavir and Atazanavir at different times depending on which 264 
drug was available and the recording of different PIs was not very accurate. 265 
We identified hypertension as being associated with developing T2DM, however, this 266 
association was not significant in the multivariable analysis. We did not assess the possible 267 
effects of the antihypertensive medicines on the risk of developing T2DM. The high burden 268 
of hypertension in this cohort illustrates the increasing burden of non-communicable 269 
diseases (NCDs) among HIV infected adults. NCDs collectively contribute to the decreased 270 
life expectancy of HIV-infected patients on treatment. Furthermore, treatment of co-271 
morbidities among PLHIV increases the pill burden and this may in turn affect adherence to 272 
medicines [26]. Men were more likely to develop T2DM in this cohort. This finding is 273 
inconsistent with global estimates that indicate that sex has little effect on diabetes. Sex 274 
distribution among diabetic patients varies widely in sub-Saharan Africa, with no discernable 275 
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trend [27]. Our study did not show any association between baseline CD4 cell count and 276 
WHO clinical stage with the risk of developing T2DM. However, other studies have found an 277 
increased risk of T2DM  with lower CD4 cell count and longer duration of HIV infection. 278 
Furthermore, studies have found associatiojns between high HIV viral load and diabets [22], 279 
[28]. 280 
The  major strength of our study was that patient characteristics are typical for many clinics 281 
in sub-Saharan Africa [29], so our results are likely to accurately reflect routine clinical care 282 
in the region. Our LTFU rate was lower than in other clinics [30], [31], hence our results were 283 
less affected by patient dropouts. Because the clinic uses an electronic record system with a 284 
rigorous data quality control system, our data was complete for all variables except baseline 285 
BMI; results were similar with and without imputing missing BMI.  286 
 287 
Our study had several limitations, chiefly because we used routine clinic data. Limitations 288 
included a lack of population based samples, absence of HIV negative, HIV positive and 289 
ART naïve comparison groups and incomplete measurement of key T2DM risk factors such 290 
as nutrition and physical exercise. The number of new-onset T2DM in our cohort was very 291 
low and this in turn limited the power of our study. In our analysis, we could not control for 292 
possible time dependent confounding because of unavailability of complete follow up data. 293 
Since all participants were enrolled at a single urban site, this may reduce the 294 
generalizability of our findings to the population of Zimbabwe and beyond.  295 
Conclusion 296 
Even though the incidence of T2DM in this HIV cohort was lower than has been observed in 297 
other cohorts, our results show that T2DM is a problem as the population of HIV-infected 298 
patients continues to age. HIV-infected patients in sub-Saharan Africa need more than ART; 299 
they need a comprehensive approach to care that includes better health services for 300 
prevention, early detection and treatment of chronic diseases.  301 
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Table 1: Participant baseline and clinical characteristics  327 
  
Variable Patients (N) 
Person 
years at 
risk 
Diabetes 
cases 
Incidence 
Rate/1000 pyrs 
(95% CI) 
Sex 
Female 2,761 14,178 30 2.12 (1.48-3.03) 
Male 1,349 6,326 27 4.27 (2.93-6.22) 
Age (years) 
<25 491 2,105 1 0.48 (0.07-3.37) 
≥25-<40 2,149 11,068 21 1.81 (1.17-2.80) 
≥40-<50 954 5,111 19 3.72 (2.37-5.83) 
≥50 402 1,916 16 8.35 (5.11-14.32) 
*BMI (kg/m2) 
<18 429 2,006 0  
≥18-<24 1,962 10,037 22 2.19 (1.44-3.33) 
>24-<30 998 5,486 22 4.01 (2.64-6.09) 
≥30 364 1,882 11 5.84 (3.24-10.55) 
WHO STAGE 
1/2 2,193 10,462 31 2.96 (2.08-4.21) 
3/4 1,917 10,041 26 2.59 (1.76-3.80) 
CD4 Count 
(cell/μl) 
<200 2,083 10,571 31 2.93 (2.06-4.17) 
≥200 2,027 9,933 26 2.62 (1.78-3.84) 
Hypertension 
Yes 638 4170 24 5.75 (3.86-5.89) 
No 3,472 16,333 33 2.02 (1.44-2.84) 
PI Use 
Yes 734 4,750 20 4.22 (2.72-6.53) 
No 3,376 15,759 37 2.35 (1.70-2.24) 
NVP Use 
Yes 2,934 16,443 49 2.98 (2.25-3.94) 
No 1,176 4,067 8 1.97 (0.99-3.94) 
EFV Use 
Yes 846 2,037 3 1.47 (0.47-4.57) 
No 3,264 18,466 54 2.92 (2.24-3.82) 
 328 
BMI=Body Mass Index; T2DM= diabetes mellitus; CI= confidence intervals,PI = Protease 329 
Inhibitor; NVP=Nevirapine; EFV=Efavirenz; WHO= World Health Organisation 330 
 331 
 332 
 333 
 334 
 335 
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Table 2: Factors associated with new-onset T2DM among HIV infected patients 336 
    
 Univariable Analysis 
Multivariable Analysis 
(based on multiple 
imputation) 
Multivariable Analysis 
(complete case analysis; 
n=3 753) 
Characteristics HR (95% CI) P  aHR (95 CI) P  aHR (95 CI) P  
Male gender 2.01 (1.20-3.40) 0.040 2.13 (1.22- 3.72) 0.01 2.31 (1.30- 4.13) 0.004 
Age > 40yrs 3.08 (1.80-5.28) 0.001 2.16 (1.22-3.83) 0.01 2.32 (1.29-4.16) 0.005 
WHO stage 3/4 0.84 (0.52-1.47) 0.611 0.76 (0.44-1.31) 0.32  0.76 (0.44-1.33) 0.34 
BMI > 30 kg/m2 2.33 (1.20-4.50) 0.010 2.26 (1.17-4.36) 0.01 3.10 (1.51-6.36) 0.002 
CD4<200 cells/µl 0.89 (0.53-1.50) 0.220 0.67 (0.38-1.18) 0.17  0.73 (0.41-1.30) 0.28 
Hypertension 
PI use 
3.94 (2.34-6.65) 
1.80 (1.04-3.09) 
0.000 
0.032 
1.79 (1.02-3.12) 
- 
0.04 
- 
 
1.60 (0.91-2.84) 
- 
0.11 
- 
Hypertension= Receiving antihypertensive medication or documented diagnosis of hypertension; BMI=Body Mass 337 
Index; aHR = adjusted Hazard ratios, PI=Protease Inhibitor, PI use excluded from multivariable analysis because 338 
it is the causal pathway for T2DM 339 
 340 
  341 
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